JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Speech rehabilitation and complications of primary tracheoesophageal puncture.

Fifty-nine patients underwent tracheoesophageal puncture during laryngectomy, and a voice prosthesis was inserted into the tracheoesophageal fistula to enable alaryngeal speech. For 68% of the 59 patients, tracheoesophageal speech was feasible right after surgery, and postoperative complications occurred in 9 of these 59. The results show that primary tracheoesophageal puncture is advantageous for alaryngeal speech rehabilitation. Eighty-two percent of the 22 patients who survived more than 4 years after surgery continued with tracheoesophageal speech, and 16 complications occurred over a longer term in 13 of the 22 patients. Since 75% of these long-term complications could be overcome by surgical treatment, close observation of the tracheoesophageal fistula and adequate treatment are needed for patients with tracheoesophageal speech and making use of a voice prosthesis.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app